TRPV1 Antagonists and Chronic Pain: Beyond Thermal Perception

• Main Authors: Michael R. Brandt, Chad E. Beyer, Stephen M. Stahl
• Format: Article
• Language: English
• Published: MDPI AG 2012-02-01
• Series: Pharmaceuticals
• Subjects: allelic variants; chronic pain; mechanotransduction; neuropathic pain; osteoarthritis; Transient Receptor Potential Vanilloid 1 (TRPV1)
• Online Access: http://www.mdpi.com/1424-8247/5/2/114/

In the last decade, considerable evidence as accumulated to support the development of Transient Receptor Potential Vanilloid 1 (TRPV1) antagonists for the treatment of various chronic pain conditions. Whereas there is a widely accepted rationale for the development of TRPV1 antagonists for the treatment of various inflammatory pain conditions, their development for indications of chronic pain, where conditions of tactical, mechanical and spontaneous pain predominate, is less clear. Preclinical localization and expression studies provide a firm foundation for the use of molecules targeting TRPV1 for conditions of bone pain, osteoarthritis and neuropathic pain. Selective TRPV1 antagonists weakly attenuate tactile and mechanical hypersensivity and are partially effective for behavioral and electrophysiological endpoints that incorporate aspects of spontaneous pain. While initial studies with TRPV1 antagonist in normal human subjects indicate a loss of warm thermal perception, clinical studies assessing allelic variants suggests that TRPV1 may mediate other sensory modalities under certain conditions. The focus of this review is to summarize the current perspectives of TRPV1 for the treatment of conditions beyond those with a primary thermal sensitivity.